AGMB - AgomAb Therapeutics NV

12.08
-0.100   -0.828%

Share volume: 90,390
Last Updated: 05-12-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$12.18
-0.10
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-0.41%
1 Month
15.93%
3 Months
-21.25%
6 Months
-17.54%
1 Year
-17.54%
2 Year
-17.54%
Key data
Stock price
$12.08
P/E Ratio 
N/A
DAY RANGE
$11.48 - $12.44
EPS 
N/A
52 WEEK RANGE
$9.00 - $17.45
52 WEEK CHANGE
-$17.54
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$97,747
AVERAGE 30 VOLUME 
$147,602
Company detail
CEO: Tim Knotnerus
Region: US
Website: www.agomab.com
Employees: 62
IPO year: 2026
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our principal executive offices are located in Antwerpen, Belgium.

Recent news